NYSE - Nasdaq Real Time Price USD
Bausch Health Companies Inc. (BHC)
6.89 +0.86 (+14.26%)
At close: July 31 at 4:00:02 PM EDT
6.95 +0.06 (+0.87%)
After hours: July 31 at 7:59:53 PM EDT
Trade BHC on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for BHC
- Previous Close
6.03 - Open
6.00 - Bid 6.80 x 1130000
- Ask 6.81 x 490000
- Day's Range
5.98 - 6.91 - 52 Week Range
4.33 - 8.69 - Volume
16,939,823 - Avg. Volume
2,813,769 - Market Cap (intraday)
2.577B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-2.94 - Earnings Date (est.) Oct 28, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
7.50
Recent News
View More
Performance Overview
Trailing total returns as of 7/31/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
BHC
1.43%
S&P/TSX Composite index (^GSPTSE)
10.54%
1-Year Return
BHC
16.98%
S&P/TSX Composite index (^GSPTSE)
29.22%
3-Year Return
BHC
29.04%
S&P/TSX Composite index (^GSPTSE)
70.78%
5-Year Return
BHC
76.44%
S&P/TSX Composite index (^GSPTSE)
73.63%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 7/31/2026
Market Cap
2.58B
Enterprise Value
21.53B
Trailing P/E
13.31
Forward P/E
1.56
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
--
Enterprise Value/Revenue
1.98
Enterprise Value/EBITDA
10.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.12%
Return on Assets (ttm)
6.57%
Return on Equity (ttm)
--
Revenue (ttm)
10.85B
Net Income Avi to Common (ttm)
-1.1B
Diluted EPS (ttm)
-2.94
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.43B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
6.89
+14.26%
Mkt Cap 2.577B
Industry Drug Manufacturers—Specialty & Generic
26.37
-0.34%
Mkt Cap 13.17B
Industry Drug Manufacturers—Specialty & Generic
18.32
-0.97%
Mkt Cap 5.85B
Industry Drug Manufacturers—Specialty & Generic
35.01
-1.13%
Mkt Cap 40.797B
Industry Drug Manufacturers—Specialty & Generic
10.11
-1.94%
Mkt Cap 1.399B
Industry Drug Manufacturers—Specialty & Generic
17.09
-0.93%
Mkt Cap 54.577B
Industry Drug Manufacturers—Specialty & Generic
2.8300
-2.08%
Mkt Cap 1.057B
Industry Drug Manufacturers—Specialty & Generic
11.85
+0.17%
Mkt Cap 9.871B
Industry Drug Manufacturers—Specialty & Generic
20.31
-2.12%
Mkt Cap 2.258B
Industry Drug Manufacturers—Specialty & Generic
26.41
-2.08%
Mkt Cap 1.039B
Industry Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreDropping Coverage of Bausch Health Companies
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
Placing Both Bausch Entities Under Review Following Mixed Court Ruling on Xifaxan Patent Case
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetEnd of an Era as Papa Leaves Bausch's Board; Shares Still Trade Below FVE After 18% Gain
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
This edition features putting the Bausch & Lomb spinoff under our lens, the regulation of utility companies, wagering on Tabcorp, and International Flavors & Fragrances, BlackRock, and Fortinet.